Longeveron - Spark Newswire

6 minute read

Biotech
General
Health Care
News
Penny Stocks

Longeveron Announces Potential Biomarker Correlating with Lomecel-B Bioactivity

Today, 5:43 PM

Lomecel-B significantly decreased biomarker Tie-2 in Aging Frailty subjects at 270 days compared to placebo Significant, dose-dependent decrease in Tie-2 at Day 270 Oral presentation today at the International Conference for Frailty & Sarcopenia Research

LGVN

7 minute read

Biotech
General
Penny Stocks

Longeveron Announces Final Results of Phase 1 Clinical Study of Lomecel-B Injection in Hypoplastic Left Heart Syndrome Patients

By Longeveron

Today, 5:43 PM

--Study meets primary safety endpoint: no major adverse cardiac events (MACE), nor any treatment-related infections during the first month post-treatment.

LGVN